Results of multivariate analysis on predictors for progression of clinical joint damage in patients with PsA
| Variable | Relative rate of joint damage progression (95% CI) | p Value |
|---|---|---|
| Duration of disease at first visit (group 2 vs group 1) | 1.38 (1.08 to 1.77) | 0.01 |
| Age (1 year increase) | 1.03 (1.02 to 10.4) | <0.0001 |
| Sex (men vs women) | 1.02 (0.81 to 1.29) | 0.84 |
| Education status at first visit (college or university vs less than high school) | 0.82 (0.64 to 1.06) | 0.13 |
| Calendar time of clinic entry | 0.77 (0.66 to 0.89) | 0.0005 |
| Clinical joint damage at first visit (1 unit increase) | 1.03 (1.01 to 1.05) | 0.001 |
| NSAID at first visit (yes vs no) | 1.12 (0.87 to 1.45) | 0.38 |
| Biological agents at first visit (yes vs no) | 0.98 (0.59 to 1.62) | 0.94 |
| DMARD at first visit (yes vs no) | 1.33 (1.03 to 1.70) | 0.03 |
| NSAID after first visit (yes vs no) | 1.44 (0.96 to 2.16) | 0.08 |
| Biological agents after first visit (yes vs no) | 1.43 (1.11 to 1.83) | 0.006 |
| DMARD after first visit (yes vs no) | 1.62 (1.17 to 2.24) | 0.003 |
DMARD, disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis.